Shifting clones: CLL evolution under pirtobrutinib treatment
Abstract
Therapeutic targeting of Bruton tyrosine kinase (BTK), a key component of B-cell receptor signaling has transformed care in patients with chronic lymphocytic leukemia (CLL).With the increasing number of BTK inhibitors (BTKi) currently under investigation for CLL treatment, questions remain regarding the sequence and durations of treatment with the different BTKi.In this issue of Blood, Brown et al 1 present a pioneering study on genetic changes associated with pirtobrutinib resistance vs those associated with pirtobrutinib response in heavily-pretreated patients.
Fields of Study & Subjects
Chronic Lymphocytic Leukemia Research
Chronic Myeloid Leukemia Treatments
Lymphoma Diagnosis and Treatment
Publication details
- Journal / source
- Blood
- Publisher
- American Society of Hematology
- Volume
- 147
- Issue
- 1
- Pages
- 3–4
- Publication date
- 1 January 2026
- Language
- EN